Akari Therapeutics, a prominent biotechnology company focusing on developing innovative Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for cancer treatment, is set to be a part of the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. The event, scheduled to take place virtually from August 19-21, 2025, will feature Akari Therapeutics presenting on Tuesday, August 19th at 2:00 PM ET. Abizer Gaslightwala, the President and Chief Executive Officer of Akari, will be the presenter during the webinar.
Webull Financial, a well-known online brokerage platform, is hosting the webinar series, aiming to equip self-directed investors with advanced tools and technology for trading. With a commitment to offering low-cost trading, cutting-edge charting tools, and real-time market data, Webull is transforming the investment landscape. The user-centric approach and dedication to keeping pace with industry trends highlight Webull’s mission to provide a seamless and rewarding experience for traders worldwide. Webull Financial, along with its affiliates, caters to millions of users across 180 countries, offering securities and futures trading services.
Akari Therapeutics specializes in oncology biotechnology, particularly in developing unique payload antibody drug conjugates (ADCs). The Company’s primary payload, PH1, functions as a spliceosome modulator designed to disrupt RNA splicing within cells. PH1 stands out due to its distinct mechanism of action against cancer cells compared to conventional ADC payloads utilizing Topoisomerase1 or tubulin inhibitors. Preclinical studies have demonstrated that PH1 induces cancer cell death while activating immune cells, leading to robust and long-lasting efficacy. Leveraging this innovative payload, Akari can create various ADC molecules tailored to different cancer targets. AKTX-101, the lead candidate, targets the Trop2 receptor on cancer cells, delivering the novel PH1 payload directly into the tumor. In preclinical trials, AKTX-101 exhibited significant activity and extended survival rates, surpassing traditional ADCs in terms of efficacy. Moreover, AKTX-101 has shown potential for synergistic effects with checkpoint inhibitors, resulting in enhanced survival rates both as a monotherapy and in combination with checkpoint inhibitors.
Akari Therapeutics continues to accumulate validating data on its unique payload, PH1, to advance its lead asset and explore other undisclosed targets utilizing this innovation. For more insights into the company and its developments, interested individuals can visit Akari’s official website and connect with them on social media platforms like X and LinkedIn.
Key Takeaways:
– Akari Therapeutics is participating in the Webull Financial Corporate Connect Webinar Series to present its innovative work on Antibody Drug Conjugates (ADCs) for cancer treatment.
– Webull Financial, a leading online brokerage platform, is hosting the event, emphasizing low-cost trading, advanced charting tools, and real-time market data for investors worldwide.
– Akari’s primary payload, PH1, disrupts RNA splicing within cancer cells, showcasing unique mechanisms of action compared to traditional ADC payloads.
– AKTX-101, Akari’s lead candidate, has demonstrated promising efficacy in preclinical studies, indicating potential synergies with checkpoint inhibitors for enhanced cancer treatment outcomes.
Tags: biotech
Read more on finance.yahoo.com